Cargando...

Identification of existing drugs that effectively target NTRK1- and ROS1-rearrangements in lung cancer

PURPOSE: Efforts to discover drugs that overcome resistance to targeted therapies in patients with rare oncogenic alterations, such as NTRK1- and ROS1-rearrangements, are complicated by the cost and protracted timeline of drug discovery. EXPERIMENTAL DESIGN: In an effort to identify inhibitors of NT...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: Chong, Curtis R., Bahcall, Magda, Capelletti, Marzia, Kosaka, Takayuki, Ercan, Dalia, Sim, Taebo, Sholl, Lynette M., Nishino, Mizuki, Johnson, Bruce E., Gray, Nathanael S., Jänne, Pasi A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5203969/
https://ncbi.nlm.nih.gov/pubmed/27370605
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1601
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!